Cantor Fitzgerald is maintaining a bearish stance on equities, cautioning that the recent market rebound which has been driven largely by investor positioning—is likely behind us. The firm ...

Cantor Fitzgerald analyst Steve Seedhouse assumed coverage of ProQR Therapeutics (PRQR) with an Overweight rating and $8 price target ProQR is a leader in RNA editing and the initial biomarker ...

Cantor Fitzgerald, SoftBank Group, Tether, and Bitfinex have joined hands to launch Twenty One. The consortium of traditional finance (TradFi) and decentralized finance (DeFi) firms announced on ...

Cantor Fitzgerald is set to launch a $3 billion Bitcoin investment initiative in collaboration with SoftBank, Tether, and Bitfinex, according to a report by the Financial Times. The project ...

On Monday, Cantor Fitzgerald analysts revised their stance on Onto Innovation Inc. (NYSE:ONTO), downgrading the stock from Overweight to Neutral and significantly reducing the price target to $135 ...

Brandon Lutnick, chair of investment banking firm Cantor Fitzgerald, is reportedly partnering with SoftBank, Tether and Bitfinex to create a $3 billion crypto acquisition company. Lutnick and the ...

Fintel reports that on May 7, 2025, Cantor Fitzgerald downgraded their outlook for Marvell Technology (BMV:MRVL1) from Overweight to Neutral. There are 1,188 funds or institutions reporting ...

Fintel reports that on May 5, 2025, Cantor Fitzgerald downgraded their outlook for Onto Innovation (BMV:ONTO) from Overweight to Neutral. There are 501 funds or institutions reporting positions in ...

On Tuesday, Cantor Fitzgerald analyst Sarah James reaffirmed an Overweight rating on CVS Health (NYSE:CVS) with a steady price target of $71.00. The rating aligns with the company’s strong ...

Brandon Lutnick, chairman of Cantor Fitzgerald and son of U.S. Commerce Secretary Howard Lutnick, is leading a significant Bitcoin investment initiative. The venture will operate under a new ...